Ladenburg Thalmann initiated coverage on Nano-X Imaging with a new price target
$NNOX
Medical Electronics
Health Care
Ladenburg Thalmann initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $52.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2025 | $23.00 | Buy | D. Boral Capital |
| 9/8/2023 | $14.50 | Buy | Alliance Global Partners |
| 1/5/2023 | $21.00 | Overweight | Cantor Fitzgerald |
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 2025 Conference Call. The live webcast of the conference call may be ac
EXRAY, leading Czech radiography supplier with 50%+ market penetration, to distribute Nanox's imaging solutions PETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (("Nanox" or the "Company", NASDAQ:NNOX), an innovative medical imaging technology company, today announced a distribution agreement with EXRAY s.r.o ("EXRAY"), a leading Czech distributor of medical imaging systems, to introduce Nanox's advanced imaging solutions to healthcare providers across the Czech Republic. Under the terms of the agreement, EXRAY will lead the market introduction, sales and service of Nanox's medical imaging solution, the Nanox.ARC, a multi-source digital tomosynthesis system tha
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Artificial intelligence (AI) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (WHO), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
6-K - Nano-X Imaging Ltd. (0001795251) (Filer)
D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00
Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50
Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
4 - Nano-X Imaging Ltd. (0001795251) (Issuer)
3 - Nano-X Imaging Ltd. (0001795251) (Issuer)
PETACH TIKVA, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2025, before market open on Thursday, November 20, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q3 2025 Conference Call. The live webcast of the conference call may be ac
Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the second quarter ended June 30, 2025 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the second quarter of 2025, compared to $2.7 million in the second quarter of 2024.Grew Nanox.ARC system sales funnel exponentially in the quarter.The Company notified the FD
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, 2025, before market open on Tuesday, August 12, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q2 2025 Conference Call. The live webcast of the conference call may be accessed by
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)
SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)
NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we